

# INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES

[ISSN: 0975-4725; CODEN(USA):IJPS00] Journal Homepage: https://www.ijpsjournal.com



### **Research Article**

# Analytical Method Development And Validation For The Terlipressin In Pharmaceutical Doasage Form By RP-HPLC

# Bhagyashri S. Dhange\*, Madhav A. Shetkar, Sidheshwar S. Patil

Maharashtra college of pharmacy, Dept of Quality Assurance, Nilanga-413521 Dist. Latur Maharashtra, India.

#### ARTICLE INFO

Received: 05 May 2024 Accepted: 09 May 2024 Published: 18 May 2024 Keywords: Terlipressin, RP-HPLC, Acetonitrile, Methanol, Water, method validation. DOI: 10.5281/zenodo.11214748

#### ABSTRACT

Another methodology was set up for synchronous estimation of a Terlipressin by RP-HPLC system. The chromatographic conditions were viably created for the unit of Terlipressin by using Inertsil – ODS C18 (250 x 4.6 mm 5 $\mu$ ), stream is 1.0 ml/min, convenient stage extent was Methanol:Acetonitrile (30:70), recognizable proof wave length was 225 nm.

### **INTRODUCTION**

Terlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that accts as a vasoconstrictor. It is a prodrug of lypressin, or lysine vasopressin. Compared to endogenous vasopressin, Terlipressin has a longer half-life and increased selectivity for the V1 receptor. Molecular formula is C52H74N16O15S2.



Figure no. - 1

The Literature survey indicates that there are no methods for the Estimation of Terlipressin.

\*Corresponding Author: Bhagyashri S. Dhange

Address: Maharashtra college of pharmacy, Dept of Quality Assurance, Nilanga-413521 Dist. Latur Maharashtra, India. Email 🔄 : bhagyashridhange12@gmail.com

**Relevant conflicts of interest/financial disclosures**: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Therefore, an attempt was made to develop and validate a simple and economical RP-HPLC method as per ICH guidelines for the estimation of Terlipressin pharmaceutical dosage forms.

### MATERIALS AND METHODS:

### **Instrument:**

- HPLC waters model no. 2690/5 series compact system consisting of Inertsil-c18 ODS column
- Electronic balance
- Sonicator
- Chemical:
- Methanol HPLC grade
- Acetonitrile HPLC grade
- Buffer (KH2PO4) HPLC grade
- Water HPLC grade

# **Experimental conditions:**

Quantitative HPLC was performed on isocratic HPLC of Waters model no. 2690/5 with software Empower-2 infinity isocratic LC manual injector with variable wavelength detector. For method development several trials were carried out. chromatographic After many trials, the conditions were decided. The separation was conducted by using column of Inertsil- ODS C18  $(5\mu, 4.6 \text{ mm} \times 250)$  with mobile phase consisting of methanol and Acetonitrile in the ratio of (30:70). The mobile phase delivered at the flow rate of 1.0ml/min. The eluent was monitored at wavelength 225 nm and found a sharp and symmetrical peak with retention time of 3.68 min. The run time observed was 6 min.

### **Preparation of standard solution:**

Take 100mg Terlipressin working standard in 100ml V.F add methanol sonicate it 30min, (That is 1000ppm solution).

### Preparation of sample solution:

Take 10ml of above solution in 100ml V.F add Methanol up to mark sonicate it 10min (That 100ppm solution)

# Diluent:

The methanol was used as diluent.

# Method validation:

Validation establish a documented evidence which provides which a high degree of assurance that a specific process will consistently produce a product meeting its predetermined specifications and quality attributes.

# 1. System Suitability:

A Standard solution was prepared by using Terlipressin working standard as per test method and was injected Five times into the HPLC system. The system suitability parameters were evaluated from standard chromatograms by calculating the % RSD from five replicate injections for Terlipressin, retention times and peak areas.

# 2. Precision:

- a. System precision: Standard solution prepared as per test method and injected five times.
- b. Method precision: Prepared six sample preparations individually using single as per test method and injected each solution.

### **3.Accuracy:**

A study of Accuracy was conducted. Drug Assay was performed in triplicate as per test method with equivalent amount of Terlipressin into each volumetric flask for each spike level to get the concentration of Terlipressin equivalent to 50%, 100%, and 150% of the labelled amount as per the test method. The average % recovery of Terlipressin was calculated.

### 4.Linearity:

A Series of solutions are prepared using Terlipressin working standard at concentration levels from 20ppm to 70 ppm of target concentration.

### 5. Ruggedness:

System to system variability study was conducted on different HPLC systems, under similar conditions at different times. Six samples were prepared and each was analysed as per test method. Comparison of both the results obtained on two different HPLC systems, shows that the assay test method is rugged for System to system variability



#### **6.Robustness:**

A study was conducted to determine the effect of variation in flow rate. Standard solution prepared as per the test method was injected into the HPLC system using flow rates, 1.0ml/min and 1.2ml/min. The system suitability parameters were evaluated and found to be within the limits for 1.0ml/min and 1.2ml/min flow. Terlipressin was resolved from all other peaks and the retention times were comparable with those obtained for mobile phase having flow rates 1.0ml/min.

7.LODAnd LOQ (Limit Of Detection And Limit Of Quantitation):

From the linearity plot the LOD and LOQ are calculated:





Figure no. 2 - chromatogram for diluent







Figure no. 4 - Chromatogram Standard



Methanol: Acetonitrile (30:70)V/V. Sonicate it 30min, Filter this mobile phase through 0.45micron filter paper.

**Optimized Method Stock Solution Preparation** : Take 100mg Terlipressin working standard in 100ml V.F add methanol sonicate it 30min, (That is 1000ppm solution).

#### **Further Dilution (or) Optimized Method Solutions Preparation:**

Take 4ml of above solution in 100ml V.F add Methanol up to mark sonicate it 10min (That 40ppm solution).

Table 1. chromatographic condition				
Parameters	Method			
Stationary phase (column)	Inertsil -ODS $C_{18}(250 \text{ x} 4.6 \text{ mm}, 5 \mu)$			
Mobile Phase	Methanol: Acetonitrile (30:70)			
Flow rate (ml/min)	1.0 ml/min			
Run time (minutes)	6 min			
Column temperature (°C)	Ambient			
Volume of injection loop (µl)	20			
Detection wavelength (nm)	225nm			

#### Chromatographic conditions : Table 1 : chromatographic condition

#### Table 2 : Data of System Suitability

Injection	RT	Peak Area	USP Plate count	USP Tailing
1	3.683	645478.48	10621	1.101
2	3.684	645449.32	10630	1.103
3	3.684	645455.29	10632	1.101
4	3.683	645423.23	10645	1.103
5	3.685	645480.63	10650	1.102
Mean	3.6838	645457.39	10635	1.102
SD	0.000837	23.5654		
% RSD	0.022712	0.00365		

 Table 3 : Data System precision

Comporting	Injection	Peak Areas of Terlipressin	%Assay
	1	645440.56	100.22
40ppm	2	645480.24	100.22
	3	645471.28	100.22
	4	645423.23	100.21
	5	645462.64	100.22
Statistical Analysis	Mean	645455.59	100.22
	SD	23.3268	0.00363
	% RSD	0.00361	0.00362

#### Table 4 : Data Method precision

	Injection	Peak Areas of Terlipressin	%Assay
Concentration	1	645522.29	100.23
40ppm	2	645499.64	100.23
	3	645531.85	100.23
	4	645481.56	100.22
	5	645539.93	100.23
	6	645510.45	100.23
	Mean	645514.28	100.23
	SD	21.5888	0.00336



	Statistical Analysis		% RSD	0.00334		0.00335			
		Tal	ble 5 : Data	of Accura	cy				
Concentratio % of spiked le	n vel	Area	Amount added (ppm)	Amount found (ppm)	Re	% covery	Sta o	tistical A f % Rec	Analysis covery
50% Sample	1	322742.02	20	19.98	9	9.94	м	EAN	100.22
50% Sample 2	2	322769.61	20	20.10	10	00.52	1VI 0/-	DSD	0.326
50% Sample 3	3	322728.59	20	20.10	10	00.51	70	KSD	0.550
100 % Sample	1	645512.85	40	40.09	10	00.23	Μ	EAN	100.42
100 % Sample	2	645489.56	40	40.20	10	00.51			
100% Sample	3	645530.51	40	40.20	10	00.52	%	RSD	0.1651
150% Sample	1	968148.53	60	60.19	10	00.31	Μ	EAN	100.44
150% Sample	2	968125.94	60	60.30	10	00.50	%	RSD	0.1104
150%Sample	3	968165.54	60	60.30	10	00.51			

Bhagyashri S. Dhange, Int. J. of Pharm. Sci., 2024, Vol 2, Issue 5, 947-953 |Research

#### **Table 6 : Data of Linearity**

Concentration (ppm)	Average Area	Statistical Analysis	
0	0	Slope	16054
20	322716.85	y-Intercept	1854
30	484074.36	Correlation Coefficient	0.999
40	645432.45		
50	806790.56		
60	968148.84		
70	1120456.95		



Fig no. 5 - Linearity Plot (Concentration Vs Response) Table 7 : Data on System Variability System(Ruggedness)

Sr. No:	Peak area	Assay % of Terlipressin
1	645488.73	100.22
2	645410.82	100.21
3	645466.89	100.22
4	645419.83	100.21
5	645452.88	100.22

6	645492.21	100.23
Mean	645455.22	100.22
%RSD	0.005302	0.00531

 Table 8 : Data for Effect of variation in flow rate(Robustness)

	Std Area	Tailing factor		Std Area	Tailing factor		Std Area	Tailing factor
Flore	640125.54	1.119	Flore	645444.52	1.123	Flore	650184.85	1.136
10W	640181.45	1.123	FlOW 1.0 ml	645489.23	1.125	F10W	650136.85	1.138
0.0 111	640144.44	1.125	1.0 111	645512.12	1.123	1.4 1111	650148.36	1.137
	640138.84	1.129		645463.52	1.124		650163.36	1.137
	640152.15	1.131		645475.57	1.125		650196.65	1.136
Avg	640148.48	1.125	Avg	645476.99	1.124	Avg	650166.01	1.137
SD	20.8325	0.0047	SD	25.6012	0.001	SD	24.8123	0.0008
%RSD	0.003254	0.4242	%RSD	0.00396	0.0889	%RSD	0.00381	0.0735

#### Table 9 : Assay of formulation

Injection	Peak Areas of Terlipressin	%Assay
1	645415.33	100.22
2	645231.08	100.19
3	646087.47	100.32
4	649175.34	100.8
5	645671.08	100.26
Mean	646316.06	100.358
SD	1630.3551	0.251833
% RSD	0.25225	0.250935

#### **CONCLUSION :**

Different parameters were studied to create the analytical approach. For starters, the maximum absorbance of Terlipressin was discovered to be 225nm. The injection volume was set at 20µl, which resulted in a nice peak area. The Inertsil C18 column was employed in this work, and ODS picked a nice peak shape. The temperature of the ambient environment was determined to be adequate for the type of the medication solution. Because of the good peak area, adequate retention duration, and good resolution, the flow rate was set at 1.0ml/min. Different mobile phase ratios were investigated, however the mobile phase with a Methanol: Acetonitrile (30:70) ratio was chosen because to its symmetrical peaks and high resolution. As a result, the planned research made use of this mobile phase. The accuracy of both the system and the procedure was determined to be precise and well within range. The correlation

coefficient and curve fitting were discovered during the linearity investigation. For both medicines, the analytical approach was shown to be linear throughout a range of 20-70ppm of the target concentration. Both robustness and ruggedness tests were passed by the analytical. The relative standard deviation in both circumstances was excellent.

#### **ACKNOWLEDGEMENTS**:

Authors are thankful to for providing working standard & express their sincere gratitude towards Dr M. A. Shetkar (Research guide) Maharashtra college of pharmacy Nilanga), And Dr S. S. Patil Principal, Maharashtra College of Pharmacy, Nilanga for providing necessary facilities to carry out research work.

#### **REFERENCES :**

1. V. Gupta, A.D. K. Jain, N.S. Gill, K. Gupta, Development and validation of HPLC method



- a review, Int. Res J Pharm. App Sci., (2012);2(4) 17-25

- 2. Y. Kazakevich, R. Lobrutto, HPLC for Pharmaceutical Scientists, John Wiley & Sons, New Jersey, 2007.
- S. Ahuja, H. Rasmussen, Development for Pharmaceuticals, Separation Science and Technology, Elsevier, New York [2007] Vol.8
- 4. M.S. Azim, M. Mitra, P.S. Bhasin, HPLC method development and validation: A review, Int. Res. J. Pharm. (2013);4(4):39-46.
- B.V. Rao, G.N. Sowjanya1, A. Ajitha, V.U.M. Rao, Review on stability indicating HPLC method development, World Journal of Pharmacy and Pharmaceutical Sciences, (2015);4(8)405-423.
- M.S. Charde, A.S. Welankiwar, J. Kumar, Method development by liquid chromatography with validation, International Journal of Pharmaceutical Chemistry, (2014);04(02): 57-61.
- S. Sood, R. Bala, N.S. Gill, Method development and validation using HPLC technique – A review, Journal of Drug Discovery and Therapeutics, 2014; 2(22): 18-24.
- M.W. Dong, Modern Hplc for practicing scientists, John Wiley & Sons, New Jersey, 2006.
- P.K. Singh, M. Pande, L.K. Singh, R.B. Tripathi, steps to be considered during method development and validation for analysis of residual solvents by gas chromatography, Int. Res J Pharm. App Sci., (2013); 3(5):74-80.

- B. Prathap, G.H.S. Rao, G. Devdass, A. Dey, N. Harikrishna, Review on Stability Indicating HPLC Method Development, International Journal of Innovative Pharmaceutical Research, (2012); 3(3): 229-237.
- 11. B. Sriguru, N.P. Nandha, A.S.Vairale, A.V. Sherikar, V. Nalamothu, Development and validation of stability indicating HPLC method for the estimation of 5-Fluorouracil and related substances in topical formulation, Int. J. Res. Pharm. Sci. (2010); 1(2): 78-85.
- C.K. Kaushal, B. Srivastava, A process of method development: A chromatographic approach, J. Chem. Pharm. Res. (2010); 2(2): 519-545.
- N.Toomula, A. Kumar, S.D.Kumar, V.S. Bheemidi, Development and Validation of Analytical Methods for Pharmaceuticals, J Anal Bioanal Techniques. (2011); 2(5): 1-4.
- 14. 14. K. Kardani, N. Gurav, B. Solanki, P. Patel,
  B. Patel, RP-HPLC Method Development and
  Validation of Gallic acid inPolyherbal Tablet
  Formulation, Journal of Applied
  Pharmaceutical Science. (2013); 3(5): 37-42.
- 15. B. Nigovic, A. Mornar, M. Sertic, Chromatography – The Most Versatile Method of Chemical Analysis, Intech (2012) 385-425.

HOW TO CITE: Bhagyashri S. Dhange, Madhav A. Shetkar, Sidheshwar S. Patil, Analytical Method Development And Validation For The Terlipressin In Pharmaceutical Doasage Form By RP-HPLC, Int. J. of Pharm. Sci., 2024, Vol 2, Issue 5, 947-953. https://doi.org/10.5281/zenodo.11214748

